Antiretroviral Agents in HIV-1 (trial)

DHHS Adult HIV 2013

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/309990

Contents of this Issue

Navigation

Page 2 of 31

1 Table 1. Indications for Initiating Antiretroviral Therapy Clinical Condition and/or CD4 Count Comments ART is recommended for all HIV-infected individuals. e strength and evidence for this recommendation vary by pretreatment CD4 count: • CD4 count <350 cells/mm 3 (AI) • CD4 count 350–500 cells/mm 3 (AII) • CD4 count >500 cells/mm 3 (BIII) Patients starting ART should be willing and able to commit to lifelong treatment and should understand the benefits and risks of therapy and the importance of adherence (AIII). Patients may choose to postpone therapy, and providers may elect to defer therapy, based on clinical and/or psychosocial factors, on a case-by-case basis. ART also is recommended for HIV-infected individuals for the prevention of transmission of HIV. e strength and evidence for this recommendation vary by transmission risks: • Perinatal transmission (AI) • Heterosexual transmission (AI) • Other transmission risk groups (AIII) Table 2. Coinfections Disease Recommendation Hepatitis B When treatment is indicated, use an ART regimen containing either tenofovir and emtricitabine OR tenofovir and lamivudine. Hepatitis C Consider ART regardless of CD4 count. If CD4 >500, may defer ART until aer HCV therapy. If CD4 <200, start ART and defer HCV therapy until aer CD4 increase. Tuberculosis (TB) The presence of active TB requires immediate a initiation of treatment (AI). • Include a rifamycin (rifabutin preferred) in regimens for patients receiving ART, with dosage adjustment if necessary (AII). Patient Status CD4 (cells/mm 3 ) Initiate ART All <50 ≤2 wk after TB Rx (AI) Severe a 50–200 2–4 wk after TB Rx (BI) >200 2–4 wk after TB Rx (BIII) Not severe 50–500 2–12 wk after TB Rx (AI) >500 2–12 wk after TB Rx (BIII) Pregnant – As early as feasible (AIII) MDR/XDR TB – 2–4 wk after confirmed Dx of resistance and initiation of 2nd-line TB therapy (BIII) a By clinical evaluation (including low Karnofsky score, low body mass index [BMI], low hemoglobin, low albumin, organ system dysfunction, or extent of disease). Assessment and Diagnosis

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (trial) - DHHS Adult HIV 2013